CN101035535A - 4-( 4-甲基哌嗪-1-基甲基)-N-[4-甲基-3-(4-(吡啶-3-基 )嘧啶-2-基氨基)苯基]-苯甲酰胺用于抑制酪氨酸激酶受体c-fms的用途 - Google Patents
4-( 4-甲基哌嗪-1-基甲基)-N-[4-甲基-3-(4-(吡啶-3-基 )嘧啶-2-基氨基)苯基]-苯甲酰胺用于抑制酪氨酸激酶受体c-fms的用途 Download PDFInfo
- Publication number
- CN101035535A CN101035535A CNA2005800338341A CN200580033834A CN101035535A CN 101035535 A CN101035535 A CN 101035535A CN A2005800338341 A CNA2005800338341 A CN A2005800338341A CN 200580033834 A CN200580033834 A CN 200580033834A CN 101035535 A CN101035535 A CN 101035535A
- Authority
- CN
- China
- Prior art keywords
- fms
- compound
- csf
- methyl
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61974404P | 2004-10-18 | 2004-10-18 | |
| US60/619,744 | 2004-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101035535A true CN101035535A (zh) | 2007-09-12 |
Family
ID=36202610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800338341A Pending CN101035535A (zh) | 2004-10-18 | 2005-10-17 | 4-( 4-甲基哌嗪-1-基甲基)-N-[4-甲基-3-(4-(吡啶-3-基 )嘧啶-2-基氨基)苯基]-苯甲酰胺用于抑制酪氨酸激酶受体c-fms的用途 |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| EP3246046A4 (en) * | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
-
2005
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Ceased
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de not_active Expired - Lifetime
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en not_active Ceased
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en not_active Expired - Lifetime
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007118420A (ru) | 2008-11-27 |
| ATE492277T1 (de) | 2011-01-15 |
| MA28946B1 (fr) | 2007-10-01 |
| JP2008516898A (ja) | 2008-05-22 |
| DE602005025514D1 (de) | 2011-02-03 |
| WO2006042362A1 (en) | 2006-04-27 |
| KR20070083705A (ko) | 2007-08-24 |
| BRPI0517083A (pt) | 2008-09-30 |
| TNSN07141A1 (en) | 2008-11-21 |
| EP1804800A4 (en) | 2008-03-19 |
| NZ554009A (en) | 2010-09-30 |
| CA2580976A1 (en) | 2006-04-27 |
| US20080255139A1 (en) | 2008-10-16 |
| IL182419A0 (en) | 2007-09-20 |
| MX2007004660A (es) | 2007-10-17 |
| EP1804800A1 (en) | 2007-07-11 |
| ZA200702316B (en) | 2008-09-25 |
| EP1804800B1 (en) | 2010-12-22 |
| AU2005297321A1 (en) | 2006-04-27 |
| NO20072501L (no) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| CA3065365C (en) | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR | |
| Orlen et al. | T-cell dependency of tumor regressions and complete responses with RAS (ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma | |
| US10314834B2 (en) | Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation | |
| KR20150054962A (ko) | 국소 진행성 유방암의 치료방법 | |
| US12516024B2 (en) | KDM4 inhibitors | |
| Saluja et al. | Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways | |
| TW201522632A (zh) | 弗林蛋白酶(furin)基因抑制及gm-csf增強(fang)之癌症疫苗 | |
| JP5576290B2 (ja) | 白血病の管理における3−(インドリル)−または3−(アザインドリル)−4−アリールマレイミド誘導体の用途 | |
| CN1921864A (zh) | 使用TGF-β抑制剂治疗神经胶质瘤 | |
| CN101146549A (zh) | 抗血管新生剂与阿地白介素 | |
| RU2630975C2 (ru) | Режим дозирования pi-3 киназы | |
| JP2014532658A (ja) | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 | |
| TWI741286B (zh) | 治療癌症之方法 | |
| JP2021536507A (ja) | Her駆動性がんを治療または予防するための化合物、組成物、及び方法 | |
| US20160303137A1 (en) | Dual pi3k and wnt pathway inhibition as a treatment for cancer | |
| Diaz-Flores et al. | PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras | |
| JP2017500369A (ja) | ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物 | |
| JP2021535198A (ja) | 膵臓癌を治療する方法 | |
| CN1874776A (zh) | 治疗慢性骨髓性白血病(cml)的4-苯胺基-3-喹啉腈 | |
| CN1960733A (zh) | 包含src激酶抑制剂azd0530和抗雌激素或egfr-tk抑制剂的组合产品 | |
| JP2024514958A (ja) | ユビキチン特異的ペプチダーゼ22(usp22)の阻害剤、並びに疾患及び障害の治療のためのその使用 | |
| JP2018511605A (ja) | 慢性骨髄性白血病癌幹細胞の成長抑制用または増殖抑制用の組成物、及びそのスクリーニング方法 | |
| WO2025157287A1 (zh) | 包含prmt5抑制剂和egfr抑制剂的药物组合物 | |
| EP1804800B1 (en) | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl¨-benzamide to inhibit the tyrosine kinase receptor c-fms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20070912 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |